These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32315368)

  • 41. Monocyte/High-Density Lipoprotein Ratio Is an Indicator of Activity in Patients with Ulcerative Colitis.
    Yalçın MS; Yalaki S; Ölmez Ş; Taş A
    Turk J Gastroenterol; 2022 Apr; 33(4):329-335. PubMed ID: 35550541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of selected laboratory markers in ulcerative colitis.
    Mańkowska-Wierzbicka D; Swora-Cwynar E; Poniedziałek B; Adamski Z; Dobrowolska A; Karczewski J
    Eur Cytokine Netw; 2015; 26(2):26-37. PubMed ID: 26463466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study.
    Yamamoto-Furusho JK; Bozada-Gutiérrez KE; Sánchez-Rodríguez A; Bojalil-Romano F; Barreto-Zuñiga R; Martínez-Benitez B
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(3):317-325. PubMed ID: 30679027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of circulating midkine in ulcerative colitis.
    Krzystek-Korpacka M; Neubauer K; Matusiewicz M
    Clin Chem Lab Med; 2009; 47(9):1085-90. PubMed ID: 19728850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis.
    Osada T; Ohkusa T; Okayasu I; Yoshida T; Hirai S; Beppu K; Shibuya T; Sakamoto N; Kobayashi O; Nagahara A; Terai T; Watanabe S
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S262-7. PubMed ID: 19120909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume.
    Yüksel O; Helvaci K; Başar O; Köklü S; Caner S; Helvaci N; Abayli E; Altiparmak E
    Platelets; 2009 Jun; 20(4):277-81. PubMed ID: 19459134
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of serum cytokine profile in ulcerative colitis assessment.
    Rodríguez-Perálvarez ML; García-Sánchez V; Villar-Pastor CM; González R; Iglesias-Flores E; Muntane J; Gómez-Camacho F
    Inflamm Bowel Dis; 2012 Oct; 18(10):1864-71. PubMed ID: 22238172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.
    Nakarai A; Kato J; Hiraoka S; Inokuchi T; Takei D; Moritou Y; Akita M; Takahashi S; Hori K; Harada K; Okada H; Yamamoto K
    World J Gastroenterol; 2014 Dec; 20(48):18367-74. PubMed ID: 25561804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.
    Xiang JY; Ouyang Q; Li GD; Xiao NP
    World J Gastroenterol; 2008 Jan; 14(1):53-7. PubMed ID: 18176961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis.
    Masoodi I; Kochhar R; Dutta U; Vaishnavi C; Prasad KK; Vaiphei K; Kaur S; Singh K
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1768-74. PubMed ID: 20136960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis.
    Soendergaard C; Nielsen OH; Seidelin JB; Kvist PH; Bjerrum JT
    Inflamm Bowel Dis; 2015 May; 21(5):1077-88. PubMed ID: 25803506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
    Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
    J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease.
    Ohman L; Dahlén R; Isaksson S; Sjöling A; Wick MJ; Sjövall H; Van Oudenhove L; Simrén M; Strid H
    Inflamm Bowel Dis; 2013 Oct; 19(11):2433-9. PubMed ID: 23966065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reticulated platelet levels in patients with ulcerative colitis.
    Kayahan H; Akarsu M; Ozcan MA; Demir S; Ates H; Unsal B; Akpinar H
    Int J Colorectal Dis; 2007 Dec; 22(12):1429-35. PubMed ID: 17549498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic immune-inflammation index as a potential biomarker to monitor ulcerative colitis.
    Yan J; Deng F; Tan Y; Zhou B; Liu D
    Curr Med Res Opin; 2023 Oct; 39(10):1321-1328. PubMed ID: 37691449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
    Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
    Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis.
    Fluxá D; Simian D; Flores L; Ibáñez P; Lubascher J; Figueroa C; Kronberg U; Pizarro G; Castro M; Piottante A; Vial MT; Quera R
    J Dig Dis; 2017 Nov; 18(11):634-641. PubMed ID: 28949435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity.
    Okba AM; Amin MM; Abdelmoaty AS; Ebada HE; Kamel AH; Allam AS; Sobhy OM
    Auto Immun Highlights; 2019 Dec; 10(1):4. PubMed ID: 32257060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.